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Abstract
Hepatitis C virus (HCV) frequently establishes persistent infections in the liver, leading to
the development of chronic hepatitis and, potentially, to liver cirrhosis and hepatocellular
carcinoma at later stages. The objective of this study was to test the ability of five Dicer sub-
strate siRNAs (DsiRNA) to inhibit HCV replication and to compare these molecules to ca-
nonical 21 nt siRNA. DsiRNA molecules were designed to target five distinct regions of the
HCV genome – the 5’ UTR and the coding regions for NS3, NS4B, NS5A or NS5B. These
molecules were transfected into Huh7.5 cells that stably harboured an HCV subgenomic
replicon expressing a firefly luciferase/neoR reporter (SGR-Feo-JFH-1) and were also test-
ed on HCVcc-infected cells. All of the DsiRNAs inhibited HCV replication in both the subge-
nomic system and HCVcc-infected cells. When DsiRNAs were transfected prior to infection
with HCVcc, the inhibition levels reached 99.5%. When directly compared, canonical siRNA
and DsiRNA exhibited similar potency of virus inhibition. Furthermore, both types of mole-
cules exhibited similar dynamics of inhibition and frequencies of resistant mutants after 21
days of treatment. Thus, DsiRNA molecules are as potent as 21 nt siRNAs for the inhibition
of HCV replication and may provide future approaches for HCV therapy if the emergence of
resistant mutants can be addressed.
Introduction
Infection with hepatitis C virus (HCV) is a worldwide public health problem, a major cause of
liver cirrhosis and hepatocellular carcinoma, and has been considered the leading indication
for liver transplantation [1]. Approximately 170 million people are chronically infected with
HCV worldwide, and studies in the USA found that deaths caused by HCV infection exceeded
those resulting from HIV infection [2]
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HCV is an RNA virus and member of the Flaviviridae family and the Hepacivirus genus.
The virus has a 9.6 kb single-stranded positive-sense genome that encodes a single polyprotein
comprising approximately 3000 amino acids flanked by 5’ and 3’ untranslated regions (UTRs).
Translation is driven in a cap-independent fashion by an internal ribosome entry site (IRES),
and both viral and host proteases cleave the polyprotein to yield 10 structural (Core, E1 and
E2) and non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B) proteins.
The infection initially causes acute hepatitis, which is often subclinical and may develop
into a chronic condition. The evolution to chronicity occurs in approximately 85% of cases [3],
and among these chronic patients, 70% develop liver pathology. Five to twenty per cent of
these pathologies are liver cirrhosis [4], and 1 to 5% of patients die from cirrhosis or hepatocel-
lular carcinoma. Approximately 30–50% of patients develop hepatocellular carcinoma after ap-
proximately 10 years of infection [5].
Until recently the standard of care for chronic HCV infection was pegylated interferon
(peg-IFN) and ribavirin (RBV) [6]. The development of novel direct acting antivirals (DAA)
targeting the NS3 protease (e.g. boceprevir, telaprevir or simeprevir), NS5A phosphoprotein
(e.g. daclatasvir) and NS5B polymerase (e.g. sofusbuvir) has revolutionised treatment [6]. The
new treatment regimens have dramatically improved the sustained virologic response (> 80%)
but, severe side-effects and the high-cost are still a problem on HCV therapy [7]. Because of
that, several new drugs are being tested at the time. However, because HCV is the most variable
virus known to man, the application of selective pressure via drug treatment will undoubtedly
lead to resistance [8,9]. Therefore, continuing to identify new drugs and more effective treat-
ments is important. In this regard, RNA interference (RNAi) has been demonstrated both in
vitro and in vivo to have the potential to treat various viral infections.
RNA interference is a process of post-transcriptional gene silencing that has been identified
in all eukaryotes [10,11]. Since its first report, this mechanism has been found to be useful both
as a molecular biology tool for the study of gene function and as a therapeutic agent [12,13]. A
key component of the RNAi pathway is the RNA-induced silencing complex (RISC), which is
responsible for the cleavage of mRNA in a sequence-specific fashion. The specificity of this re-
action is provided by a 21 nt antisense strand incorporated into the RISC complex. This anti-
sense strand originates from the digestion of double stranded RNA (dsRNA) by DICER
endonuclease [14]. Synthetic 21 nt siRNAs can be introduced into cells and can selectively sup-
press a specific gene of interest. A number of reports have shown that RNA interference can ef-
ficiently inhibit HCV replication via different methodologies [15–17].
DICER substrate siRNAs (DsiRNAs) are 25/27-nt-long asymmetrical double stranded
RNAs that can inhibit a specific mRNA sequence without activating the IFN pathway [18].
These DsiRNA are recognised by DICER enzymes and digested into smaller 21 nt dsRNA frag-
ments, which are then recognised and incorporated by the RISC complex to finally degrade the
targeted mRNA. Recent studies have shown that DsiRNAs are more potent than conventional
synthetic siRNAs [19,20].
A major drawback for therapy with RNAi for an RNA virus is the RNA-dependent RNA po-
lymerase (RdRp) responsible for viral genome replication. RdRp has a high error rate due to a
lack of proofreading activity; therefore, the mutation rates for these viruses are relatively high
[21]. The long-term treatment of cells infected with HCV or of those harbouring an SGR with
RNAi molecules induced the selection of resistant viral quasi-species, which reduced the treat-
ment efficiency [22].
In this present study, we developed five DsiRNA molecules directed to the HCV genome
and showed that these molecules could efficiently inhibit virus replication. Contrary to previ-
ous studies, we also demonstrated that DsiRNA and siRNA have the same potency for HCV in-
hibition. Moreover, we did not observe any difference in the frequency of resistant mutants
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that were selected after the treatment of subgenomic replicon (SGR)-harbouring cells with
these RNAs after 21 days.
Materials and Methods
HCV replicon constructs
SGR-Feo-JFH-1 is a bicistronic subgenomic replicon [23] based on the genotype 2a JFH-1 virus
isolate that contains a firefly luciferase gene fused to a neomycin resistance gene (Feo). FL-J6/
JFH-50C19Rluc2AUbi is a monocistronic full-length virus construct [24] based on the sequence
of J6 (genotype 2a) and JFH-1 (genotype 2a), which expresses the Renilla luciferase gene. SGR-
Feo-JFH-1 was used to produce a stable Huh7.5 cell line; FL-J6/JFH-50C19Rluc2AUbi was used
to produce HCVcc particles.
Mammalian cell culture
Huh7.5 cells [25] were cultured in DMEM (Sigma Aldrich, St. Louis, MO, USA) supplemented
with 10% (v/v) heat-inactivated foetal bovine serum (Cultilab, Campinas, SP, Brazil), 1x nones-
sential amino acids, 100 U/ml penicillin and 100 μg/ml streptomycin (Life Technologies, Carls-
bad, CA, USA) at 37°C in a 5% CO2 humidified incubator. Stable cell lines were maintained
with 800 μg/ml G418 (Sigma Aldrich).
RNA transfection of Huh7.5 cells
RNA was transcribed from plasmid templates in vitro as previously described [26]. Huh7.5
cells were electroporated following the protocol described by Amako et al. [27]. To generate
stable cell lines, 1 μg of transcribed RNA was transfected with a DMRIE-C reagent (Life Tech-
nologies) following the manufacturer’s instructions. Forty-eight hours after transfection, 800
μg/mL G418 (Sigma Aldrich) was added to the culture medium. Colony formation was ob-
served after four weeks.
DsiRNA and siRNA targeted to the HCV genome
Five Dicer substrate siRNAs (DsiRNAs) that were 25/27 nt in length were designed to target
five distinct regions of HCV mRNA: 5’UTR, NS3, NS4B, NS5A and NS5B. The DsiRNA mole-
cules (IDT) were designed according to the algorithm described by Kim et al. [18]. DsiRNA
molecules are asymmetrical, the sense strand is 25 nt long with the last two bases being DNA
and the antisense strands are composed of 27 RNA bases. Those modifications are necessary to
help Dicer processing and incorporation to the correct strand to RISC complex [28]. Two 21 nt
siRNA molecules were also designed to target the same sequence in the NS5B or NS4B coding
region as the corresponding DsiRNA. A negative control DsiRNA with no homology to any
human gene or to the HCV genome was also utilised (NC1—IDT). For canonical siRNA analy-
ses, we utilised a negative siRNA control that also lacked homology to HCV or any human
gene (Negative control 1 siRNA—Life Technologies).
DsiRNA Transfection method
SGR-Feo-JFH-1-harbouring Huh7.5 cells were trypsinised, and 3 x 104 cells/well seeded into a
24-well plate and incubated for 24 h prior to transfection. All transfections were carried out
using the RNAi-specific cationic lipid formulation Lipofectamine RNAiMAX (Life Technolo-
gies) following the manufacturer’s instructions. The transfection efficiency was monitored via
transfection with TYE 563 DS Transfection Control (IDT), a DsiRNA duplex labelled with a
fluorescent dye.
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DsiRNA transfection in HCVcc-infected Huh7.5 cells
HCVcc containing supernatant was titrated using a focus-forming assay, and Huh7.5 cells
were infected at a multiplicity of infection of 0.1. Twenty-four hours after infection, the cells
were washed twice with PBS, fresh complete medium was added to the wells, and the cells were
transfected with DsiRNA as described above. Forty-eight hours after infection, the cells were
lysed and subjected to a luciferase assay. Alternatively, the cells were first transfected with
DsiRNAs 24 h prior to infection with the infectious supernatant using the same multiplicity
of infection.
Selection of resistant mutations
To evaluate the ability of either siRNA or DsiRNA to induce the formation of resistant clones,
the cells were transfected three times (5 days apart) with siRNA, DsiRNA or the negative con-
trol molecule (NC1). Cells were initially seeded on a 24 well plate and whenever the cells ap-
proached confluence, they were trypsinised and transferred onto a larger plate. The selection
medium containing 1 mg/ml G418 (Sigma Aldrich) was changed every two days. After 21 days
of treatment, the selection medium was removed and the colonies were harvested by adding
Trizol reagent (Life Technologies).
Sequencing of resistant colonies
The total RNA was extracted from surviving colonies using Trizol (Life technologies) according
to the manufacturer's instructions. Five hundred nanograms of RNA was reverse-transcribed
using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Scientific, Wal-
tham, MA, USA). Complementary DNA was amplified using primers flanking the target region
of siRNA/DsiRNA and Phusion Hot Start II High-Fidelity DNA Polymerase (Thermo Scientif-
ic). The PCR product was subsequently cloned into a pBlunt vector (Thermo Scientific) and
transformed into Z-competent E. Coli (Zymo Research). Nineteen clones were selected and
submitted for sequencing using the BigDye Terminator (Life technologies), and the products
were sequenced in an ABI 3130XL Sequencer (Life technologies).
Luciferase assay
The cells were harvested by adding 100 μL of Passive Lysis Buffer (Promega). Twenty-five
microlitres of cell lysate were transferred to a white 96-well plate. Next, 50 μL of Luciferase sub-
strate (Luciferase Assay System, Promega or Renilla Luciferase Assay system) was automatical-
ly added, and the luminescence was read with a BMG plate reader (BMG Labtech GmbH,
Ortenberg, Germany).
Antibodies
The polyclonal sheep antiserum against HCV NS5A was described previously [29]. Monoclo-
nal antibodies to glyceraldehyde-3 phosphate dehydrogenase (GAPDH; Abcam, Cambridge,
MA, USA) were obtained commercially and used at concentrations recommended by the man-
ufacturer; HRP- (Life Technologies) secondary antibodies were used for western blotting.
Immunoblotting
The cells were lysed in Glasgow lysis buffer (GLB; 10 mM Pipes-KOH pH7.2, 120 mM KCl,
30 mMNaCl, 5 mMMgCl2, 1% Triton X-100 (Sigma), 10% glycerol) [29] supplemented
with protease and phosphatase inhibitors (2 mM Na3VO4, 5 mMNaF, 5 mM Na4P2O7). The
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proteins were resolved by SDS/PAGE and transferred to a PVDF membrane (Millipore, Bed-
ford, MA, USA).
Northern blotting
Huh7.5 cells were transfected with different concentrations of a DsiRNA molecule and 16
hours after transfection cells were harvested and RNA extracted using Trizol. Approximately
30 ug of RNA was separated by 15% denaturing Urea Polyacrylamide gel electrophoresis and
transferred to positively charged nylon membrane (Hybond N+, Amersham) using a semi-dry
blotting device. RNA was fixed to membrane by UV crosslinking and pre-hybridized for 3 h
with pre-hybridization buffer (7% SDS, 0.5% BSA, 200 mMNa2HPO4 (ph 7.0), 50 pmol/ml
denaturated salmon sperm DNA). Hybridization was carried out at 39°C for 16 h with hybrid-
ization buffer (pre-hybridization buffer containing biotinylated probe at 50 pmol/ml). Hybrid-
ized membrane was washed twice with medium stringency washing buffer (1x SSC and 0.1%
SDS), once with high stringency washing buffer (0.1x SSC and 0.1% SDS) and then incubated
with blocking buffer (10% BSA, 0.1 M Tris/HCl pH 7.5, 0.1 M NaCl, 2 mMMgCl2, 0.05% Tri-
ton X-100) for 1 hour. Blocked membrane was then incubated with streptavidin-HRP conju-
gate (GE Healthcare, 1:3000) for one hour, washed three times with washing buffer A (0.1 M
Tris/HCl pH 7.5, 0.1 M NaCl, 2 mMMgCl2, 0.05% Triton X-100) and one time with Buffer B
(0.1 M Tris/HCl pH 9.5, 0.1 M NaCl,50 mMMgCl2). ECL HRP substrate [30] was added to
the membrane and exposed for the appropriated time lengths on a chemiluminescent detection
module (ChemiDoc XRS+).
Data analysis
All experiments were performed using three technical replicates and at least two independent
events. For the inhibition assays, the data were normalised to the values of the appropriate neg-
ative control. For cytotoxicity and off-target assays, the values were normalised to mock con-
trols (cells treated with transfection reagent only). The data were analysed using Prism
Graphpad v.5.0. The results were analysed using a one-way ANOVA at a significance level of
p 0.05.
Results
To develop molecules that could efficiently inhibit HCV replication, the sequence of the HCV
genotype 2a isolate JFH-1 was screened using the bioinformatics tool RNAi Design from IDT
SciTools (IDT). Based on the algorithm developed by Kim et al. [18], the program suggested
twenty different targets in the HCV genome, which could theoretically effectively inhibit the
replication of the virus. Five sequences were selected from these options to be synthesised and
tested in vitro. The inclusion criteria for the study were the scores given by the software and the
spatial separation of the sequences across the virus genome. The exact position and sequence
of the DsiRNA molecules are summarised in Table 1.
The parameters for the efficient transfection of Huh7.5 cells with DsiRNA were established
using a fluorescent DsiRNA—the transfection efficiency routinely ranged from 85 to 90%
(Fig. 1A). Using the same transfection protocol with varying concentrations of DsiRNA in cells
stably harbouring the SGR-Feo-JFH-1, we observed that the DsiRNA directed against the
NS5B coding region could reduce the virus replication, as assessed by a luciferase assay
(Fig. 1B). As expected, the decrease in luciferase depended on the concentration of DsiRNA
used in the transfection. Concentrations as low as 0.1 nM could reduce the levels of luciferase
by more than 40% compared to the negative control. The most potent inhibition was observed
using 10 nM of DsiRNA; however, the difference between this value and the value obtained at
Comparative Study between siRNA and DsiRNA for HCV Inhibition
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5 nM was small (<5%). Therefore, the latter concentration was used in all subsequent experi-
ments. To confirm the specificity of the inhibition, the cells were transfected with a negative
control DsiRNA (IDT). Similar luciferase levels were observed between cells treated with nega-
tive control DsiRNA or mock transfected cells (transfection reagents only), which confirmed
that the reduction of luciferase levels using virus-directed DsiRNAs was specific and not an
off-target effect or a cell response to transfection (Fig. 1B). To check the cytotoxicity of the
RNAi molecules, the cells were transfected with 5 nM of the five DsiRNAs, the two canonical
siRNA and their negative controls. After 48 hours, cellular cytotoxicity was not observed for
any of the analysed molecules (Fig. 1C).
We then sought to determine whether different DsiRNAs inhibited HCV replication with
similar efficiency. As shown in Fig. 2A, DsiRNAs that targeted different regions of the viral ge-
nome inhibited HCV replication to differing extents. Forty-eight hours after transfection, all of
the DsiRNAs tested reduced HCV replication (Fig. 2) by at least 77%, with the most efficient
DsiRNA targeting the NS5B coding sequence (93% ± 2.8 reduction compared to negative con-
trol), followed by NS4B (92.8% ± 3.4), NS3 (91.6% ± 1.9), NS5A (86.8% ± 3.1) and 5’ UTR
(77.9% ± 2.7). To confirm this result, the expression of the NS5A protein was evaluated with a
western blot assay using a polyclonal NS5A antiserum. Four of the five DsiRNAs reduced the
expression of NS5A to undetectable levels, and NS5A was only detected at a low level in cells
transfected with the DsiRNA targeting the 5’UTR (Fig. 2B).
To assess whether the DsiRNAs molecules were also effective in the context of virus infec-
tion, the cells were transfected with each of the five DsiRNAs 24 h prior to infection with FL-
J6/JFH-50C19Rluc2AUbi (HCVcc). At 48 h after infection, renilla luciferase activity was re-
duced by more than 90% for all DsiRNAs, with NS4B- and NS5B-targeting DsiRNAs almost
completely abrogating HCV RNA replication (Fig. 3A). Depending on the DsiRNA tested, the
virus replication measured based on the intracellular Renilla luciferase levels was reduced by
more than 99.5% (NS5B) and 98.4% (NS4B). In comparison, when cells were infected prior to
transfection, the inhibition levels were similar to those observed in the sub-genomic replicon
Table 1. Information of DsiRNA and siRNA molecules.
Name Target Position a Sequence b
DsiRNA 1 NS5B 8914–8940 S: 5’ CAACCAUAUGGGUUCGCAUGGUCCT 3’
AS: 3’ AGGUUGGUAUACCCAAGCGUACCAGGA 5’
DsiRNA 3 NS5A 6991–7017 S: 5’ CCUGCACCACCCACAGCAACACCTA 3’
AS: 3’ GUGGACGUGGUGGGUGUCGUUGUGGAU 5’
DsiRNA 5 NS4B 5758–5784 S: 5’ CCAGUACCACCAUCCUUCUCAACAT 3’
AS: 3’ CUGGUCAUGGUGGUAGGAAGAGUUGUA 5’
DsiRNA 7 NS3 4038–4064 S: 5’ GCUCCAACUGGCAGUGGAAAGAGCA 3’
AS: 3’ UACGAGGUUGACCGUCACCUUUCUCGU 5’
DsiRNA 19 5’ UTR 42–68 S: 5’ CUGUGAGGAACUACUGUCUUCACGC 3’
AS: 3’ GGGACACUCCUUGAUGACAGAAGUGCG 5’
siD1 NS5B 8914–8934 S: 5’ CAACCAUAUGGGUUCGCAUGG 3’
AS: 3’ AGGUUGGUAUACCCAAGCGUA 5’
siD5 NS4B 5758–5778 S: 5’ CCAGUACCACCAUCCUUCUCA 3’
AS: 3’ CUGGUCAUGGUGGUAGGAAGA 5’
Probe DsiRNA 1 - 5’ BTN—ACTCCAACCATATGGGTTCGCAT 3’
a Position relative to HCV genotype 2a sequence, JFH-1 strain (AB047639);
b S: sense strand, AS: antisense strand, bolded letters represents DNA bases, BTN—biotin.
doi:10.1371/journal.pone.0117742.t001
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Fig 1. DsiRNA concentration screening. SGR-Feo-JFH-1 cells were transfected with a fluorescent
DsiRNA control (5 nM) (A) or with HCV-specific NS5B DsiRNA and 10 nM of DsiRNA negative control (NC1)
Comparative Study between siRNA and DsiRNA for HCV Inhibition
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(B). RNAi molecules do not induce cytotoxicity in SGR-Feo-JFH-1 cells at 5 nM concentration (C). The results
are shown as a percentage of the treated sample compared to the mock control (sample transfected with
media only). The data (B and C) are averages of three technical replicates and at least two biological
replicates, error bars are SD.
doi:10.1371/journal.pone.0117742.g001
Fig 2. HCV knockdown by different DsiRNAs. SGR-Feo-JFH-1 cells were transfected with 5 nM aliquots of
each DsiRNA and analysed 48 h post-transfection by measuring the luciferase levels (A) lysates and protein
expression levels (B) in cell lysates. The values are a percentage of the luciferase activity relative to the
negative control (NC1) DsiRNA-transfected cells. The labels on the X-axis indicate the region to which
DsiRNAs were directed. The data are averages of three technical replicates and at least two biological
replicates, error bars represents SD.
doi:10.1371/journal.pone.0117742.g002
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Fig 3. Inhibition of HCVcc by DsiRNAs.Huh7.5 cells were transfected with 5 nM of each DsiRNA before
(A) or after (B) infection with HCVcc (MOI of 0.1). At 48 h post-infection, the cells were lysed in PLB and the
luminescence levels were read on a BMG plate reader. The values are a percentage of the luminescence of
treated sample compared to the negative control (NC1). The data (A and B) are averages of three technical
replicates and at least three biological replicates, error bars represents SD.
doi:10.1371/journal.pone.0117742.g003
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system (Fig. 3B). The two most efficient molecules were those that targeted the coding se-
quence of NS5B (92.5%) and NS4B (90.6%).
Some studies have reported that DsiRNAmolecules are more potent than the corresponding
21-nt siRNA [18,20]. To test this hypothesis, we selected the two most potent DsiRNA mole-
cules (NS5B and NS4B targeted, DsiRNA1 and DsiRNA5, respectively) in our study and
synthesised conventional siRNAs (SiD1 and siD5) to the same HCV genome localisation
(Table 1). The two types of RNAi molecules were tested in parallel by transfecting SGR-Feo-
JFH-1-harbouring cells with concentrations ranging from 0.01 nM to 100 nM. The highest
concentrations (> 1 nM) of both molecules (directed to the NS5B region (Fig. 4A) or NS4B re-
gion (Fig. 4B)) did not result in differences in inhibition (p>0.05) after incubation for 48
hours. However, at higher dilutions (0.01 nM and 0.1 nM), the canonical siRNAs were more ef-
ficient (P<0.05) in reducing HCV replication. To elucidate the difference in the potency of
these molecules, we calculated their IC50 values. The IC50 values calculated for DsiRNA1 and
siD1 were 95.45 pM and 23.99 pM (p< 0.001), respectively. For molecules targeting the NS4B
region, the IC50 values were 88.12 pM for DsiRNA 5 and 25.04 pM for siD5 (p< 0.001).
DsiRNAs molecules are predicted to be processed by DICER endonuclease into smaller
fragments that are then incorporated by RISC complex and used as template for specific de-
struction of complementary targets. To verify that molecules were being processed by DICER,
DsiRNA 1 was transfected at different concentrations into Huh7.5 cells and total RNA was ex-
tracted from these cells 16 hours post-transfection. The presence of the 27 nt and the predicted
21 nt processed form was analyzed by northern blot using an specific biotinylated probe
(Table 1). The sensitivity of this assay was estimated at 80 fmol using synthetic 27 nt and 21 nt
molecules (data not shown). We were able to detect the 27 nt form of the DsiRNA molecule on
all transfected concentrations (10 nM, 25 nM and 50 nM) however we did not detect the 21 nt
DICER processed form at any of the tested concentrations (Fig. 5), suggesting that DICER pro-
cessing of DsiRNA was not occurring. To confirm that the probe was capable of detecting the
21 nt processed form, Huh7.5 cells were also co-transfected with the 21 nt molecule, as shown
at Fig. 5, both molecules were detected by the Northern blot assay.
The selection of mutants resistant to treatment with RNAi molecules is a common occur-
rence for RNA viruses. We tested whether the frequency of this phenomenon is similar for
DsiRNAs and canonical siRNAs. To this end, SGR-Feo-JFH-1 cells were transfected with 5 nM
of either DsiRNA1 or DsiRNA5 (NS5B or NS4B) and their 21 nt corresponding (siD1 or siD5)
and treated with G418 for up to 21 days. RNA was extracted from surviving colonies, reverse
transcribed, amplified by PCR, cloned and sequenced. When the cells were treated with
DsiRNA targeting the NS5B region, 6 of 19 clones containing mutations within the target site
were identified. When cells were treated with the corresponding siRNA, four of the 19 clones
had mutations in the target region for this molecule. A considerably smaller number of resis-
tant clones was observed for molecules directed to the NS4B region. Of the 15 clones obtained
from cells treated with DsiRNA5, 3 (3/15) had mutation at this target site. However, when cells
were transfected with siD5, only one (1/15) mutated clone was observed. Finally when cells
were treated with the negative controls, none of the 15 clones showed any change in the target
site. The nucleotides/amino acid changes, as well as the exact position of these changes, are
summarised in Fig. 6.
Discussion
In this report, we show the ability of Dicer substrate siRNAs (DsiRNAs) to inhibit HCV ge-
nome replication in vitro using both a sub-genomic and a full-length replication system. In
both models, viral replication was reduced by at least 90% using 5 nM of DsiRNAs. To our
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Fig 4. Potency comparison between DsiRNAs and 21 nt siRNAs. SGR-Feo-JFH-1 cells were transfected
with the indicated concentrations of DsiRNA or canonical siRNA for two distinct targets. At 48 h post-
infection, the cells were lysed in PLB and the luminescence levels were read on a BMG plate reader. The
values are a percentage of the luminescence of the treated sample compared to the negative control (NC1).
The data (A and B) are averages of three technical replicates and at least three biological replicates, error
bars represents SD.
doi:10.1371/journal.pone.0117742.g004
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knowledge, this report is the first to demonstrate the inhibition of HCV by these RNAi mole-
cules. We also demonstrated that unlike other studies [18,20], DsiRNA has similar or even
lower inhibition potency as 21 nt siRNAs in the context of HCV.
Off-target effects are a major concern in RNAi therapy [31]. These effects occur when a
siRNA is processed by the RNA-induced silencing complex (RISC) and alters the expression of
undesirable genes [32]. One of the main processes leading to off-target effects is the siRNA
concentration, which is directly proportional to the intensity of undesired effects [31,33]. In
general, concentrations near 100 nM are reportedly capable of eliciting non-specific effects
[32]. Because DsiRNA is described as a more potent molecule compared to other RNAi mole-
cules [18], a lesser amount of RNA may be used to achieve the desired levels of inhibition,
which reduces the likelihood of off-target effects. For this reason, we decided to test these mole-
cules for their ability to inhibit HCV.
We designed five DsiRNA molecules for different regions of the HCV genome. Three mole-
cules that targeted the NS5B, NS4B and NS3 coding regions could reduce viral replication by
more than 80%. The other two (5’ UTR and NS5A) molecules only moderately knocked down
the virus (< 70%). Although some studies have found that virus replication may be reduced
using siRNAs directed to the 5’UTR [34,35] or NS5A [16,36], our DsiRNA molecules targeting
those regions were not very efficient. Specifically, the low efficiency of the 5’UTR-targeted se-
quence is likely due to the highly structured nature of this site [37], which may hinder the bind-
ing of the DsiRNA molecule to its target sequence.
After the success of experiments with the sub-genomic system, we tested the efficacy of the
DsiRNA molecules in the context of virus infection. In this assay, two different approaches
were tested. First, Huh7.5 cells were transfected with DsiRNAs prior to infection with HCVcc,
as expected, the levels of inhibition using this approach were much better than those observed
when cells were with HCVcc 24 h prior to transfection with DsiRNAs. Overall, the levels of in-
hibition when cells were infected prior to transfection were similar to those observed in the as-
says with the sub-genomic system and described by other authors [35,38]. When directly
comparing the efficiency of the DsiRNAs against sub-genomic replicons or virus infection, our
data suggest that DsiRNAs are less effective once virus infection has been established than in
cells harbouring pre-existing subgenomic replicons. The presence of the core protein may
Fig 5. Detection of transfected RNAi by northern blot. Huh7.5 cells were transfected with different
concentrations of DsiRNA 1 after 16 hours cells were harvested and RNA extracted and tested by northern
blot for the presence of DsiRNA1 and its 21 nt DICER processed form. Untransfected DsiRNA 1 (27 nt) (A)
and siD1 (21 nt) (B) were utilized as size controls. Lanes C, D and E Huh7.5 cells transfected with 10 nM, 25
nM and 50 nM respectively. Lane F Huh7.5 co-transfected with DsiRNA1 and siD1 at 25 nM.
doi:10.1371/journal.pone.0117742.g005
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protect the nascent virus RNA from DsiRNA-mediated cleavage as a result of associating with
the virus RNA during the process of virion assembly.
Some studies showed that DsiRNA molecules were more potent in inhibiting mRNA or
viral RNA compared to canonical 21 nt siRNA [18,20]. To test this hypothesis, we synthesised
two siRNAs (21 nt) that utilised the same target used by DsiRNA1 or DsiRNA5 (termed siD1
or siD5, respectively). We did not observe any difference in the inhibition potency between
siD1 and DsiRNA1 or between siD5 and DsiRNA5 at higher concentrations (1–100nM). More-
over, 21 nt siRNAs more efficiently inhibited virus replication at lower concentrations (0.01–
0.1 nM). In a similar study, Foster et al. [39] compared the efficiency of several siRNA and
Fig 6. Nucleotide and amino acid sequences of RNAi-resistant cells. The localisation of each mutation observed in siRNA/DsiRNA resistant viral clones.
SGR-Feo-JFH-1 cells were repeatedly transfected (5-day intervals) with 5 nM of siD1/siD5 or DsiRNA1/DsiRNA5 and treated with 1 mg/mL of G418. Twenty-
one days after the first transfection, the total RNA of surviving colonies was extracted, amplified by RT-PCR and submitted for sequencing. A) Nucleotide
substitutions for NS5B target site. B) Amino acid substitutions for NS5B target site. C) Nucleotide substitutions for NS4B target site. B) Amino acid
substitutions for NS4B target site. SIN—Synonymous mutations; WT—JFH-1 wild type; Numbers after the RNAi molecule name on first column represents
the clone in which sequences were obtained.
doi:10.1371/journal.pone.0117742.g006
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DsiRNA for two human mRNA and also did not observe any difference between these two
RNAi molecules. This contradictory information suggests that the increased potency of DsiR-
NAs may be due to differences in the methodology and experimental models used by the other
authors [18,20]. Therefore, we can only affirm that siRNA and DsiRNA have similar potency
for HCV inhibition.
The two critical players in the RNAi pathway are DICER, an endoribonuclease responsible
for cleaving long (> 21 nt) double-stranded RNAs into smaller pieces with 21 nt of extension,
and the RISC complex, which is responsible for unwinding one dsRNA strand and using it as a
template to identify homologous mRNAs in order to cleave them [14]. The higher potency of
DsiRNA molecules may be the result of a previously identified link between DICER and the
RISC complex [40,41]. Previous studies [28] have demonstrated that physical parameters of
the DsiRNA molecules (e.g., asymmetry of the molecule and the addition of DNA bases in
sense strand) induce DICER to cleavage larger RNA molecules at an exact point, resulting in
only a single shorter 21 nt variant. Because we did not observe differences in the inhibition effi-
ciency between the 21 nt and 27 nt molecules, we decided to test if the DsiRNA 1 molecule was
being authentically processed by DICER. Although this molecule was designed using a software
using the algorithm described by Kim et al. (2005), Northern blot analysis demonstrated that
this molecule was not being processed in the predicted manner.
However, DsiRNA1 was still able to inhibit HCV replication efficiently, reaching levels simi-
lar to a conventional siRNA molecule. Previous studies have shown that the RISC complex is
able to incorporate larger ssRNA molecules (> 21 nt) with no change in target inhibition effi-
ciency [42]. There are extreme cases in which molecules up to 63 bp were incorporated in RISC
complex independently of processing by DICER [43] and still effectively inhibited the target
RNA. It seems likely therefore that in some cases, DsiRNAs can be directly incorporated into
the RISC complex regardless of their processing by DICER and can then act as the guide strand
to target viral RNA.
Importantly, we obtained a similar level of inhibition using a 20-fold lower concentration of
siRNA when comparing the inhibition efficiency of the siD1 molecule with other studies that
used the NS5B HCV coding sequence as a target [44–47]. Similar results were observed for
siD5, which was 5 times more potent than the siRNA that targeted the NS4B coding region
used in other studies [48]. The algorithm used to predict DsiRNA molecules was first described
by Kim et al. [18] and differs at some points from those used to predict siRNA molecules
[49–51]. In both cases, the algorithm considers several factors, including the incorporation of
transfected dsRNA into the RISC complex and the characteristics of the target region. Both
siD1 and siD5 were designed from the corresponding DsiRNA sequences and therefore fol-
lowed the published protocol for DsiRNAs [18]. This algorithm may more efficiently predict
factors that are not taken in account by other prediction software, which allows it to suggest
more potent molecules.
A well-known characteristic of HCV replication is the rapid generation of virus variants. A
single patient contains many variants of the initial infectious sequence, which are referred to as
a quasi-species [52]. These variants are the result of the high error rate of the RNA-dependent
RNA polymerase [21]. To be effective, an RNAi molecule needs to be 100% homologous to its
target sequence. Consequently, a single base change to the target sequence of a siRNA or
DsiRNA could greatly reduce the efficiency of these molecules [53]. Thus, the elevated error
rate of HCV replication may be an issue during treatments with RNAi molecules, as reported
by Konishi et al. [22].
As demonstrated by Northern blot, DsiRNA1 was not processed to the predicted 21 nt
product and as a result a single 27 nt molecule might have been incorporated into the RISC
complex [42]. Therefore the viral RNA target site for both molecules (DsiRNA 1 and siD1)
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were almost identical, except for the extra 6 nt for the larger molecule and this fact may justify
the similarity of the number of resistant colonies obtained, when these molecules were com-
pared. Also the number of resistant colonies without on-site mutations after the treatment was
relatively high and this may be explained by the transfection efficiency. Although our efficiency
was higher than 90%, even after 3 transfections a number of cells might remain untransfected.
Consequently, those untransfected/poorly transfected cells could survive the G418 treatment,
to develop colonies that were later collected and sequenced.
Moreover, the presence of mutations outside the target of RNAi molecules caught our atten-
tion. In addition to the clones identified with mutations in the NS5B or NS4B targets, we ob-
served few clones with point mutations within the limit of 100 nt 5' or 3' to the original target
site. This result was observed for cells treated with all RNAi molecules tested in this study.
However, the mutations in each clone were in different positions. These mutations outside the
target have been observed in the context of other viruses [54], and these nucleotide changes
were suggested to play a role in the emergence of resistant mutants to treatment with RNAi by
a rearrangement in the local structure of RNA, making the target region inaccessible to siRNA/
DsiRNA molecules [55]. However, mutations outside the target were also observed in cells
treated with the negative control, though these nucleotide changes were different from those
observed in cells treated with siRNA/DsiRNA. Therefore, whether these mutations had a role
in the RNAi resistance process in our study is unclear.
In this study, we reduced replication of an HCV sub-genomic replicon by more than 90%
and the replication of HCVcc virus by approximately 99% using Dicer substrate siRNAs. Con-
trary to other experimental models, we also showed that DsiRNA have similar potency as a
conventional 21-nt siRNA for the inhibition of HCV. Finally, we demonstrated that treating
the SGR-Feo JFH-1 replicon for 21 days with any of our RNAi molecules (siRNA or DsiRNA)
resulted in similar frequencies of treatment-resistant mutants. Therefore, we conclude that
DsiRNA molecules have similar potency as 21 nt siRNAs for the inhibition of HCV genome
replication and should be considered as part of future HCV therapy.
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